BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock’s Cell Therapy to Treat Heart Failure
August 24, 2022 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with BlueRock Therapeutics LP for the delivery of...
ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease
June 08, 2021 07:30 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...